The Canadian Delegates:

Transcription

1 CANADIAN BIO/PHARMA MISSION TO EU Milano, 14 November :00 Palazzo Affari ai Giureconsulti Sala Parlamentino Piazza Mercanti 2 Working with Canadian partners to accelerate your drug discovery and development projects. The strength of Canada s biopharmaceutical industry and medical research community, and its presence in the world s largest healthcare market have created a world-class drug research and development services industry. Major pharma and biotech firms and institutions from around the world work with Canadian organizations in drug discovery, synthesis, formulation and clinical evaluation. Join us at this special event and meet some of the top Canadian drug development companies and service providers. They will illustrate what many global biopharma leaders already know that the internationally recognized capabilities, quality and regulatory compliance of Canadian service providers accelerate product discovery and development, while our competitive costs and tax benefits contribute to the bottom line. Time Title * 09:00 Registration and welcome coffee 09:30 Opening of the seminar Claudio Rotti, Vice President, PROMOS Welcome and Introduction Ambassador Alex Himelfarb, Canadian Embassy Welcoming remarks Ferruccio Ceccarelli, Director, Research and Innovation, Lombardy Region Opening remarks: Canada and EU - common interests & partnership opportunities in biopharma R&D Stewart Beck, Assistant Deputy Minister, International Trade Centre for Applied Genomics Dr.Dennis McCormac, Director Platform Development 11:00 Coffee break 11:30 Caprion Proteomics - Harnessing proteomics to generate a high-quality drug & diagnostic candidates Martin Leblanc, President & CEO U-Alberta Metabolomics Platform Novel Drug Discovery High-speed target identification through metabolic profiling Ian Forsythe, Program Manager ID Labs R&D Tools for drug target discovey & validation Dr, Reza Mazaheri, President Allphase Clinical Research - Clinical trials in Canada for International drug development Angelo Panzica, COO Gowlings SRED Tax credits & making the most of your financing by leveraging Canadian strengths Helene D Iorio, Partner Closing comments Assolombarda Giorgio Basile, Advisor in charge for Research and Innovation 13:15 Lunch and Networking 14:30 Individual Meetings ALL THE SPEECHES WILL BE IN ENGLISH. NO TRANSLATION SERVICES WILL BE PROVIDED

2 Canadian Delegates: The Canadian Delegates: Allphase Clinical Research Inc. ( Angelo Panzica, COO & Dr. Philip Sinclair, Director Scientific Affairs Presentation: Developing a Winner Smart planning from pre-clinical to phase IV Canada is a central country to many global bio/pharma R&D programs, and is one of the largest participants in clinical trials. Many international companies have successfully performed clinical development in Canada, and have benefited from Canada s competitive R&D costs, tax credits, large network of GCP clinical sites, well characterized patient populations, high regulatory standards, and robust IP protection. The scientific expertise and international knowledge of Canadian CROs make Canada an excellent launching pad for products destined for markets around the world. Allphase Clinical Research is a full-service, quality focused CRO dedicated to helping clients achieve their clinical development goals. Allphase collaborates with clients through all stages of development, providing comprehensive services in Regulatory Management, Data Management (EDC or paper), Trial Planning and Monitoring, Project Management, Training, Medical Writing, and Quality Assurance. Allphase s experience and knowledge of the scientific, regulatory, and logistical elements of clinical research allow us to provide operational support and strategic insight into any clinical project. Diligent application of industry best practices ensures that our clients projects are managed in strict compliance with industry regulations and laws. Allphase provides full Phase I- IV services in all major therapeutic areas, with particular strengths in Oncology, Cardiovascular, CNS and Respiratory diseases. We have strong relationships with medical experts in these fields, and a vast network of top Canadian researchers in our proprietary database. In addition, Allphase employees are members of industry associations such as DIA, ACRP, AAAAI, and ASCO. Allphase thrives on challenge and endeavor to achieve success at every stage in order to be your trusted outsourcing partner. Allphase Clinical Research is dedicated to Exceeding Your Expectations. Caprion Proteomics Inc. ( Martin Leblanc, President & CEO Presentation: Filling the Pipeline Harnessing proteomics to generate a high-quality drug & diagnostic candidates Caprion offers proprietary proteomics technology under the brand CellCarta that accurately profiles proteins, peptides and biomarkers in cells to identify and validate disease markers, drug targets and mechanisms of drug action. Caprion s technology can generate whole therapeutic pipelines in areas such as cancer and infectious disease, as well as identifying high value biomarkers for diagnostics.

3 The CellCarta platform has broad applications and can be used to identify disease biomarkers in blood, plasma and cell samples, as well as identifying unique markers on various cancerous tumours. They have also applied the technology to animal models to identify host and pathogen proteins in cases of infection. The power of this approach has been validated by their numerous partnerships with pharma multinationals for whom they have provided solid diagnostic and treatment targets for novel small molecule and antibody therapies. Gowlings, Lafleur, Henderson LLP ( Helene D Iorio, Partner (Montreal) Presentation: Doing Business in Canada Strategies for protecting your intellectual property and benefiting from R&D tax incentives in Canada Gowlings Partners Carole Chouinard (Tax) and Hélène D'Iorio (IP) will demystify the lucrative Canadian Scientific Research and Development (SRED) program and strategies for protecting your intellectual property in Canada. Gowlings is Canada s leading full service law firm with over 750 professionals of which 150 work for clients in the Life Sciences industry. Gowlings is globally recognized and peer recommended for its expertise in intellectual property law, employment law, transfer pricing, regulatory law, class action litigation, and financial and corporate services. Our team-based approach provides legal and business solutions tailored to the needs of our off shore pharmaceutical and other life sciences clients who have chosen to do business in Canada. Gowlings recently opened an office in London, England expanding its international presence which includes its Moscow office, which was been serving clients for over a decade. The Centre for Applied Genomics ( Dr. Dennis McCormac, Director Platform Development Presentation: Applied Genomics Translating genomics discoveries into clinical applications TCAG is advancing projects aimed at developing therapeutics and diagnostics for genetic diseases and disorders. The Centre is active in the identification of targets for drug and gene therapy, genetic variation in disease states, and profiling of populations with genetic diseases such as autism, cystic fibrosis, and certain forms of epilepsy and cancer. By understanding the genetic basis of disease, TCAG can compile vast databases of genetic information, such as the Database of Genomic Variants ( which has led to the development of genome-wide microarray technologies. The Centre for Applied Genomics (TCAG) is a research organization, led by world-renowned geneticist Dr.Steven Scherer, providing applied genomics technologies and services to companies and institutions in the bio/pharma field. TCAG is a core facility within the Research Institute at The Hospital for Sick Children, and is a Science and Technology Platform of Genome Canada. TCAG also houses vast databases of genetic information and applies advanced techniques in bioinformatics to specifically identify disease causes and potential therapeutic targets. 3

4 TCAG collaborates with multinational pharma companies and major research institutions on research and development programs for specific diseases and genetic therapies. The Centre provides services to over 1,100 laboratories worldwide in a variety of genomic and genetic disciplines, including health, biotechnology, agriculture and food sciences. TCAG also provides consultative resources related to genomics project design and implementation, access to high performance computing, bioinformatics support and data analysis. University of Alberta Metabolomics Platform (UAMP) ( Ian Forsythe, Program Manager Presentation: Metabolic Profiling Characterizing disease states for better therapeutic strategies. The University of Alberta is a world leader in human metabolomics and metabolic profiling. It is home to unique and internationally important databases and chemical libraries including DrugBank, DrugMet (the drug metabolite library), the Human Metabolome Database and the Human Metabolome Library. These resources, combined with nearly $7 million in state-of-the-art equipment and 20 specially trained personnel, allow the University of Alberta Metabolomics Platform (UAMP) to rapidly and inexpensively identify, quantify and contextualize thousands of metabolites or xenobiotics from almost any biological sample. This capacity is many times greater than any other commercial or academic facility in the world. ID Labs Biotechnology Inc. ( Dr. Reza Mazaheri, President & Scientific Director Over the past 14 years, ID Labs has provided innovative products and custom molecular biology and immunologic research services for cutting-edge Laboratory Medicine to customers around the world. ID Labs products include a wide range of gene and chromosome specific probes, immunochemicals and diagnostic kits. ID Labs continues its commitment to provide rapid, international technical sales support and expertise to end users through its international offices and its growing network of global distributors. To best serve our American and Canadian customers, the North American Head Office has expanded to include a new space at the recently created Biotechnology Commercialization Center at University Research Park in London, Ontario. ID Labs also maintains an office near Sydney, Australia to serve our growing client base in the Pacific Rim, and we proudly maintain an office in the UK for the convenience of our European customers. At ID Labs our first commitment is to you, the life science, medical, drug-discovery and biotechnology investigator. With our growing team of highly qualified professional staff, associates, manufacturers and distributors, ID Labs provides the high quality, reliable tools and services you need to execute your research projects. Phenomenome Discoveries Inc. ( John Hyshka 4

5 Phenomenome Discoveries Inc. (PDI) is a human health research company that uses its patented metabolomic biomarker discovery platform and patented informatic research tools to discover novel metabolite biomarkers. PDI has small molecule serum biomarker discovery programs in cancer and neurodegenerative disease, and has validated and filed patents on diagnostic biomarkers in multiple human health disorders. PDI is uniquely positioned within the market, offering expertise in discovery and subsequent elucidation of the biological relevance of biomarkers as well as the development of highly efficient targeted assays for validated, relevant biomarkers. Since inception, PDI has conducted hundreds of successful biomarker discovery projects on a fee for service basis, in addition to growing its internal and collaborative research network. In late 2007, PDI incorporated a personalized metabolic health research and monitoring subsidiary, which will open its first research center in Saskatoon in VIDO (Vaccine & Infectious Disease Organization) ( Paul Hodgson The University of Saskatchewan s Vaccine and Infectious Disease Organization (VIDO) is a world leader in the research and development of vaccine and immunity-enhancing technologies for humans and animals. VIDO is a non-profit organization owned by the University of Saskatchewan and operates with support from the governments of Alberta and Saskatchewan, Government of Canada, industry competitive grants, and charitable foundations. In recent history, immunization has had a profound impact on saving lives, preventing an estimated two million deaths per year. Yet despite advances in available technology, vaccine delivery techniques have not greatly improved, leaving some populations inadequately protected. VIDO is developing novel vaccine formulation and delivery systems including powerful, naturallyderived vaccine additives and needle-free methods. Much of this work is applicable across species and diseases. In an interdisciplinary environment, VIDO is working to improve the health of humans and animals, and reduce suffering caused by diseases like influenza and hepatitis C, and by the lack of effective vaccines for newborns and populations in developing countries. Government of Alberta ( Carmen Killick, Director Trade & Investment / Europe The Government of Alberta has helped to build a strong provincial research base through its commitment to attract, establish and retain world-class researchers and companies. Alberta has developed significant expertise in many areas, including: - Bone and Joint Research - Cancer - especially Reovirus, Vaccines, Diagnostics, and Epidemiology - Cardiovascular Research - Diabetes and Islet Transplantation Research - Edmonton Protocol - Vaccines for Infectious Diseases 5

6 Alberta is emerging as a dynamic base for expanding health and bio-industries. Award winning researchers, outstanding infrastructure, and innovative company developments are the core elements of this growing sector. All of these factors work together to capitalize on the province's enviable research and development capabilities. Government of Ontario Ministry of Economic Development & Trade ( Cheryl Donais, Business Development Officer Mike Harling, Business Development Consultant Venues Attending: All Canada leads the world in bio firms per capita, with Ontario home to more than half the country's brand-name pharmaceutical and medical devices companies, and almost half of the medical biotechnology industry. Ontario's biotechnology industry: - Over 5,000 employees - Canada's largest - and North America's 3rd largest hub of biotech firms - Over 150 companies and 60 research centres - Generates over half of Canada's biotech revenues (over $2.3 billion annually) Ontario's pharmaceutical industry: - Over 16,000 employees - Annual revenues over $7.5 billion - Home to over half of Canada s pharmaceutical companies, including key operations of major multinationals such as GlaxoSmithKline, AstraZeneca and Eli Lilly - Pharmaceutical R&D expenditures nearing $500 million annually 6